| 1424 |
National Cancer Institute |
Html |
en |
Liver (Hepatocellular) Cancer Screening (PDQ®)–Health Professional Version |
Expert-reviewed information summary about tests used to detect or screen for liver (hepatocellular) cancer. |
| positive predictive value | 0.503935 |
| Needle aspiration cytology | 0.492344 |
| 10-year survival rates | 0.485559 |
| hepatitis B virus | 0.608203 |
| hepatitis G infection | 0.516552 |
| control group | 0.576587 |
| 6-monthly AFP assays | 0.575205 |
| North America | 0.429041 |
| nonalcoholic steatohepatitis | 0.42282 |
| AFP screening | 0.526835 |
| usual-care group | 0.429439 |
| ethnic groups | 0.421496 |
| test result | 0.419937 |
| HCC | 0.942449 |
| screening group | 0.63461 |
| Age-standardized incidence rates | 0.541219 |
| hepatitis B infection | 0.498394 |
| glycogen storage disease | 0.517803 |
| porphyria cutanea tarda | 0.523911 |
| new cases | 0.427232 |
| patients experience pain | 0.502381 |
| Serum AFP | 0.49956 |
| fetal-specific glycoprotein antigen | 0.51455 |
| United States | 0.614175 |
|
| screening tests | 0.450593 |
| retrospective case-control study | 0.516703 |
| mortality rate ratio | 0.509505 |
| certain Aspergillus species | 0.510442 |
| widely used tumor | 0.501438 |
| cryptogenic cirrhosis | 0.452869 |
| earlier diagnosis | 0.555097 |
| right upper quadrant | 0.485875 |
| common cancer | 0.432709 |
| surface antigen–positive carriers | 0.524371 |
| diagnosis study designs. | 0.509206 |
| Chinese Americans | 0.422068 |
| high incidence | 0.419907 |
| distinct male preponderance | 0.54002 |
| risk factor | 0.421115 |
| HCC mortality | 0.712636 |
| mortality rate | 0.512472 |
| randomized controlled trial | 0.492498 |
| alcoholic cirrhosis | 0.45216 |
| chronic hepatitis | 0.816099 |
| germ cell tumors | 0.509004 |
| liver biopsy | 0.576034 |
| annual risk | 0.42449 |
| liver cancer | 0.48682 |
|
CLICK HERE |
| 1460 |
National Cancer Institute |
Html |
en |
Adjustment to Cancer: Anxiety and Distress (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the difficult emotional responses many cancer patients experience. This summary focuses on normal adjustment issues, psychosocial distress, and adjustment disorders. |
| cancer treatment | 0.348496 |
| adjustment disorders | 0.377426 |
| newly diagnosed cancer | 0.338474 |
| palliative care specialist | 0.336033 |
| emotional distress | 0.481089 |
| recurrent breast cancer | 0.355658 |
| ambulatory cancer patients | 0.342576 |
| psychological distress | 0.361971 |
| Japanese cancer patients | 0.3428 |
| Cancer Network Distress | 0.42624 |
| early-stage breast cancer | 0.450601 |
| adult cancer patients | 0.342011 |
| posttreatment distress | 0.33562 |
| health care professionals | 0.348864 |
| normal adjustment | 0.438186 |
| adolescent cancer patients | 0.355821 |
| social support | 0.338806 |
| breast cancer patients | 0.4182 |
| patients | 0.62456 |
| cancer patients | 0.6025 |
| normal adjustment issues | 0.349617 |
| cancer diagnosis | 0.33963 |
| breast cancer survivors | 0.37097 |
| mental disorders | 0.352228 |
| psychosocial distress | 0.487249 |
|
| adjustment | 0.494267 |
| women | 0.328737 |
| distress | 0.685449 |
| psychosocial assessment | 0.364194 |
| study | 0.349859 |
| distress scores | 0.331169 |
| stage breast cancer | 0.326706 |
| breast cancer diagnosis | 0.330404 |
| palliative care | 0.44264 |
| cancer-related life events | 0.334421 |
| life | 0.404419 |
| posttreatment cancer-related distress | 0.396788 |
| general distress indices | 0.342126 |
| primary oncology team | 0.360914 |
| diagnostic criteria | 0.346926 |
| psychosocial assessment interview | 0.338281 |
| Community Cancer Care | 0.328482 |
| advanced cancer | 0.337588 |
| breast cancer | 0.994793 |
| mental disorder | 0.347463 |
| psychological well-being | 0.349655 |
| Psychosocial Distress section | 0.403402 |
| general distress | 0.349587 |
| major depressive disorder | 0.329474 |
|
CLICK HERE |
| 1590 |
National Cancer Institute |
Html |
en |
Adjustment to Cancer: Anxiety and Distress (PDQ®)–Patient Version |
Expert-reviewed information summary about the difficult emotional responses many cancer patients experience. This summary focuses on normal adjustment issues, psychosocial distress, and adjustment disorders. |
| cancer treatment | 0.390955 |
| mental health | 0.376414 |
| emotional distress | 0.342467 |
| mild anxiety | 0.297125 |
| Anxiety disorder—A condition | 0.322854 |
| long-term cancer survivors | 0.290225 |
| following PDQ summaries | 0.289376 |
| PDQ cancer information | 0.401693 |
| clinical trial search | 0.290488 |
| clinical trials | 0.374063 |
| cancer information summary | 0.360243 |
| normal adjustment | 0.315173 |
| Cancer education sessions | 0.292812 |
| patients | 0.858745 |
| cancer diagnosis | 0.420677 |
| mental health problem | 0.344798 |
| symptoms | 0.369957 |
| anxiety | 0.674027 |
| NCI PDQ cancer | 0.318604 |
| cancer survivors | 0.307582 |
| anxiety disorder | 0.421462 |
| great anxiety | 0.289049 |
| problems | 0.310639 |
| distress | 0.498316 |
| treatment | 0.584321 |
|
| cancer prevention | 0.287279 |
| NCI-supported cancer | 0.289072 |
| palliative care | 0.307485 |
| Cancer Information Service | 0.302564 |
| life | 0.319995 |
| generalized anxiety disorder | 0.307665 |
| cancer patients | 0.396085 |
| National Cancer Institute | 0.357347 |
| Cancer Care | 0.313891 |
| adjustment disorder | 0.323889 |
| Palliative Care Editorial | 0.287821 |
| Cancer Care page | 0.291913 |
| Care Editorial Board | 0.290774 |
| anxiety disorders | 0.412812 |
| stressful event | 0.352734 |
| fast heart beat | 0.32985 |
| PDQ summary | 0.441306 |
| intense anxiety | 0.302865 |
| cancer clinical trials | 0.331141 |
| cancer information summaries | 0.300508 |
| comprehensive cancer information | 0.300154 |
| cancer | 0.962959 |
| information | 0.418397 |
| depression | 0.295223 |
|
CLICK HERE |
| 1938 |
National Cancer Institute |
Html |
es |
Grados de comprobación científica de los estudios sobre el tratamiento del cáncer en adultos y niños (PDQ®)–Versión para profesionales de salud |
Información sobre cómo evaluar la solidez de los datos probatorios que se obtienen de diferentes clases de estudios sobre el tratamiento del cáncer. |
| Visuals Online | 0.667636 |
| Physician Data Query | 0.729238 |
| Benhaddad A | 0.68991 |
| oro —el ensayo | 0.814208 |
| estadÃstico kappa | 0.695883 |
| valoración indirectos | 0.767699 |
| hipótesis prospectivas explÃcitas | 0.790489 |
| amputación vs | 0.700012 |
| único diseño | 0.677496 |
| marcadores indirectos | 0.945889 |
|
| National Cancer Institute | 0.71653 |
| alto efectos | 0.677847 |
| subsequent large randomized | 0.778241 |
| controlled trials | 0.698624 |
| Grégoire G | 0.694845 |
| siguientes riesgos | 0.670189 |
| valores lÃmite | 0.703358 |
| Instituto Nacional | 0.973244 |
| historia clÃnica | 0.690891 |
|
CLICK HERE |
| 3518 |
National Cancer Institute |
Html |
en |
Use of Placebos |
Information about placebos and their role in cancer clinical trials. |
| new treatment | 0.545554 |
| study | 0.364583 |
| patients | 0.362034 |
| medicine | 0.367624 |
| way | 0.414648 |
| treatment group | 0.529513 |
| to. | 0.361225 |
|
| doctors | 0.371883 |
| treatment clinical trials | 0.815475 |
| bias | 0.382394 |
| Placebos | 0.570523 |
| standard treatment | 0.968379 |
| cancer | 0.37398 |
|
CLICK HERE |
| 15486 |
National Cancer Institute |
Html |
es |
Delirio |
¿Qué es delirio? Delirio es un estado mental confuse. Se explican las causas de delirio, formas de tratarlo y preguntas para hacer al doctor. |
| delirio hiperactivo | 0.974791 |
|
|
CLICK HERE |
| 15633 |
National Cancer Institute |
Html |
en |
Step 1: Application Development & Submission |
There are nine research grant application types, each with specific procedures. Learn more about developing, submitting, and tracking a cancer research grant application. |
| small project application | 0.562018 |
| grant application types | 0.615791 |
| Funding Opportunity Announcement | 0.657432 |
| grant applications | 0.709584 |
| institution business official | 0.474155 |
| Grants.gov Tracking Number | 0.523008 |
| ongoing extramural activity | 0.49934 |
| NIH’s Application | 0.521892 |
| Grants.gov Registration | 0.46434 |
| application requirements | 0.476818 |
| Administrative Supplement Request | 0.466071 |
| specific receipt date | 0.531978 |
| grant type | 0.487204 |
| specific IC program | 0.505666 |
| peer review processes | 0.498397 |
| prior approval | 0.560178 |
| well-defined scientific area | 0.49086 |
| eRA Commons | 0.962876 |
| receipt date | 0.604332 |
| Electronic grant applications | 0.606906 |
| NIH Guide | 0.481058 |
| program announcement | 0.579666 |
|
| NCI Grant Policies | 0.586226 |
| sam registration | 0.473955 |
| scientific peer review | 0.497797 |
| Small Business Innovation | 0.484684 |
| application status changes—the | 0.535723 |
| NCI Funding Opportunities | 0.538102 |
| NIH | 0.523095 |
| recent budget project | 0.476777 |
| Scientific Review Group | 0.50345 |
| NCI RFA | 0.467797 |
| application submission deadline | 0.550381 |
| grant support | 0.469498 |
| important application basics | 0.5838 |
| strong application | 0.469473 |
| application | 0.872468 |
| application cycles | 0.489855 |
| final assembled application | 0.53419 |
| additional prior approval | 0.492691 |
| grant application | 0.737304 |
| standing receipt date | 0.526741 |
| Small Business Technology | 0.489507 |
|
CLICK HERE |
| 15712 |
National Cancer Institute |
Html |
es |
Desigualdades en salud por cáncer |
El NCI está trabajando para entender y responder a las desigualdades en salud por cáncer, como lo son los índices más altos de mortalidad, menos frecuencia en el uso de exámenes de detección comprobados e índices más altos en el diagnóstico de cánceres avanzados en ciertos grupos de la población en comparación con otros. |
| maneras—desde investigación | 0.583129 |
| Cancer Health Equity | 0.613363 |
| NCI compartirán bioespecÃmenes | 0.668631 |
| representación en investigación | 0.519297 |
| simple documentación | 0.53423 |
| muertes prematuras | 0.553886 |
| Continuing Umbrella | 0.5389 |
| baja representación | 0.511204 |
| complejo sistema | 0.519795 |
| Asociación Americana | 0.686768 |
| programa partnerships | 0.505377 |
| atención sanitaria. cambios | 0.67163 |
| seguro médico | 0.780854 |
|
| Research Experiences | 0.529795 |
| Instituto Nacional | 0.508992 |
| darán forma | 0.516718 |
| Estados Unidos. | 0.527127 |
| programa cure | 0.518838 |
| múltiples barreras | 0.536273 |
| Ascendencia Africana | 0.530463 |
| Affordable Care Act | 0.638752 |
| Estudio Genético | 0.515417 |
| cabo estudios | 0.5272 |
| continuo académico | 0.516307 |
| cáncer—desde acceso | 0.547555 |
| Sociedad Americana Contra El Cáncer | 0.968768 |
|
CLICK HERE |
| 15881 |
National Cancer Institute |
Html |
es |
Cardo mariano (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos sobre el uso del cardo mariano como tratamiento para personas con cáncer. |
| único antÃdoto | 0.424085 |
| efectos anticancerÃgenos directos | 0.448877 |
| Centro Nacional | 0.438096 |
| Silybum marianum | 0.427074 |
| múltiples transfusiones | 0.423127 |
| New Hampshire Avenue | 0.426894 |
| nombres legalon | 0.423938 |
| Edad Media | 0.422184 |
| Drug Administration | 0.416696 |
| leucemia linfoblástica aguda | 0.553126 |
| NCI Best Case | 0.448513 |
| vÃa oral | 0.423383 |
| datos bibliográficos pubmed | 0.428946 |
| larga historia | 0.423907 |
| siguientes preguntas | 0.415539 |
| Comisión Alemana E | 0.439565 |
| siguientes riesgos | 0.419206 |
| antiguos griegos | 0.424579 |
| Instituto Nacional | 0.546708 |
| raras ocasiones | 0.42203 |
|
| Salud Complementaria | 0.459564 |
| Visuals Online | 0.419468 |
| complementarias revisa | 0.427116 |
| siguientes efectos | 0.430145 |
| Physician Data Query | 0.511692 |
| Estados Unidos | 0.98357 |
| gobierno alemán | 0.419217 |
| libre uso | 0.423309 |
| cabo estudios | 0.428996 |
| cuello uterino | 0.423208 |
| cardo lechero | 0.591346 |
| nombre botánico | 0.423968 |
| Santa MarÃa | 0.422174 |
| página manejo | 0.418166 |
| cardo mariano ayuda | 0.71222 |
| ¿El tratamiento | 0.434743 |
| ¿Los beneficios | 0.41683 |
| juntos cam | 0.416094 |
| Series Program | 0.416547 |
| medicina complementaria | 0.871118 |
|
CLICK HERE |
| 16857 |
National Cancer Institute |
Html |
en |
Prior Approval Requests |
null |
| recipient institution | 0.428349 |
| current policies | 0.408224 |
| NoA | 0.327733 |
| NIH recipients | 0.49032 |
| enforcement action | 0.408587 |
| latitude | 0.326586 |
| prior approval requests | 0.721397 |
| specific prior approval | 0.686294 |
| grants management specialist | 0.645519 |
| certain degree | 0.434218 |
| copies | 0.318206 |
| prior approval authority | 0.69999 |
| terms | 0.318069 |
| prior approval | 0.984844 |
| unanticipated requirements | 0.40335 |
| total costs | 0.405045 |
| Questions | 0.317851 |
| makes certain budget | 0.539233 |
| NIH Grants Policy | 0.559485 |
| limits | 0.321806 |
| email | 0.319573 |
| recipient’s discretion | 0.470347 |
| cc | 0.322104 |
|
| termination | 0.321773 |
| Circumstances | 0.323427 |
| types | 0.321678 |
| cases | 0.320114 |
| subject line | 0.413724 |
| budget categories | 0.540205 |
| Statement | 0.318087 |
| GMO | 0.360575 |
| disallowance | 0.318052 |
| grants management officer | 0.531732 |
| proposed change | 0.416195 |
| agency authority | 0.407763 |
| NCI program director | 0.515619 |
| unauthorized officials | 0.411596 |
| PD/PI | 0.318695 |
| undertakes particular activities | 0.523 |
| expenditures | 0.324868 |
| response | 0.318742 |
| post-award changes | 0.427573 |
| grant number | 0.410914 |
| unanticipated needs | 0.427883 |
| responses | 0.319676 |
| risk | 0.318261 |
|
CLICK HERE |